SANGAMO THERAPEUTICS INC
SGMO
SGMO was delisted on the 4th of May, 2026.
210 hedge funds and large institutions have $767M invested in SANGAMO THERAPEUTICS INC in 2020 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 55 increasing their positions, 69 reducing their positions, and 25 closing their positions.
29% more call options, than puts
Call options by funds: $14.1M | Put options by funds: $11M
28% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 25
11% more capital invested
Capital invested by funds: $691M → $767M (+$76.4M)
3.17% more ownership
Funds ownership: 54.73% → 57.9% (+3.2%)
2% more funds holding
Funds holding: 205 → 210 (+5)
20% less repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 69
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$14.3M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$10.7M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$7.17M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$6.08M |
| 5 |
Millennium Management
New York
|
+$5.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.91M |
| 2 |
CC
Casdin Capital
New York
|
-$4.06M |
| 3 |
Two Sigma Investments
New York
|
-$3.74M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.74M |
| 5 |
Nordea Investment Management
Stockholm,
Sweden
|
-$3.54M |
SGMO Hedge Fund Activity: Q3 2020 in Review
210 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q3 2020, worth a combined $767M — up 11% from $691M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new SGMO positions and 25 closed out — a net gain of 7 holders — while 55 added to existing stakes and 69 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $14.3M. The largest seller was BlackRock, cutting an estimated $4.91M.
- 210 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q3 2020, up from 205 in Q2 2020.
- Funds reported $767M of SANGAMO THERAPEUTICS INC stock for Q3 2020, up 11% quarter-over-quarter.
- 32 funds opened new SANGAMO THERAPEUTICS INC positions in Q3 2020 and 25 closed out, a net change of +7 holders.
- The largest SANGAMO THERAPEUTICS INC buyer in Q3 2020 was Renaissance Technologies, an estimated $14.3M added.
- The largest SANGAMO THERAPEUTICS INC seller in Q3 2020 was BlackRock, an estimated $4.91M sold.
Based on aggregated 13F filings for Q3 2020.